Management Options in Atrial Fibrillation – The Role of Vernakalant

REVIEW, January 2012, VOL II ISSUE I, ISSN 2042-4884
10.5083/ejcm.20424884.61 , Cite or Link Using DOI
Creating a Digital Object Identifier Link

A digital object identifier (DOI) can be used to cite and link to electronic documents. A DOI is guaranteed never to change, so you can use it to link permanently to electronic documents.

To find a document using a DOI

  1. Copy the DOI of the document you want to open.
    The correct format for citing a DOI is as follows: doi:10.1016/S0140-6736(08)61345-8
  2. Open the following DOI site in your browser:
    dx.doi.org
  3. Enter the entire DOI citation in the text box provided, and then click Go.
    The document that matches the DOI citation will display in your browser window.

The DOI scheme is administered by the International DOI Foundation. Many of the world's leading publishers have come together to build a DOI-based document linking scheme known as CrossRef.

Stefan H. Hohnloser, Sami A. Omar

Atrial Fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice and is associated with significant mortality and morbidity mainly due to thromboembolic complications and heart failure. Furthermore, it is an important contributor to the increasing costs of healthcare. This article provides a short summary of our current knowledge related to some important aspects of AF. Particular emphasis is given to chemical restoration of sinus rhythm by means of intravenous administration of vernakalant (Brinavess®, Merck Sharp & Dohme Ltd, UK), a novel antiarrhythmic agent that has been approved in the EU and is undergoing marketing approval in the USA.